Directed Evolution to Low Nanomolar Affinity of a Tumor-Targeting Epidermal Growth Factor Receptor-Binding Affibody Molecule

Journal of Molecular Biology

Volumn 376, Issue 5, 2008, Pages 1388-1402

  Friedman, Mikaela ^a   Orlova, Anna ^b,c   Johansson, Eva ^b   Eriksson, Tove L J ^b   Höidén Guthenberg, Ingmarie ^b   Tolmachev, Vladimir ^b,c,d   Nilsson, Fredrik Y ^b,c   Ståhl, Stefan ^a  

^a ALBANOVA UNIVERSITY CENTER   (Sweden)

^b Affibody AB   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody; affinity maturation; EGFR; phage display selection; tumor targeting

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INDIUM 111; OLIGONUCLEOTIDE;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; DISSOCIATION CONSTANT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; ISOTOPE LABELING; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RECEPTOR BINDING;

EID: 39149087035     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.12.060     Document Type: Article

References (58)

1. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev., Mol. Cell Biol. 2 (2001) 127-137
2. Wells A. EGF receptor. Int. J. Biochem. Cell Biol. 31 (1999) 637-643
3. Vermeer P.D., Einwalter L.A., Moninger T.O., Rokhlina T., Kern J.A., Zabner J., and Welsh M.J. Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature 422 (2003) 322-326
4. Libermann T.A., Nusbaum H.R., Razon N., Kris R., Lax I., Soreq H., et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313 (1985) 144-147
5. Kleihues P., and Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-Oncol. 1 (1999) 44-51
6. Kleihues P., and Ohgaki H. Phenotype vs genotype in the evolution of astrocytic brain tumors. Toxicol. Pathol. 28 (2000) 164-170
7. Rikimaru K., Tadokoro K., Yamamoto T., Enomoto S., and Tsuchida N. Gene amplification and overexpression of epidermal growth factor receptor in squamous cell carcinoma of the head and neck. Head Neck 14 (1992) 8-13
8. Santini J., Formento J.L., Francoual M., Milano G., Schneider M., Dassonville O., and Demard F. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13 (1991) 132-139
9. Harney J.V., Liebert M., Wedemeyer G., Washington R., Stein J., Buchsbaum D., et al. The expression of epidermal growth factor receptor on human bladder cancer: potential use in radioimmunoscintigraphy. J. Urol. 146 (1991) 227-231
10. Neal D.E., Sharples L., Smith K., Fennelly J., Hall R.R., and Harris A.L. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65 (1990) 1619-1625
11. Sauter G., Haley J., Chew K., Kerschmann R., Moore D., Carroll P., et al. Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int. J. Cancer 57 (1994) 508-514
12. Gardmark T., Wester K., De la Torre M., Carlsson J., and Malmstrom P.U. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int. 95 (2005) 982-986
13. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol./Hematol. 19 (1995) 183-232
14. Rocha-Lima C.M., Soares H.P., Raez L.E., and Singal R. EGFR targeting of solid tumors. Cancer Control 14 (2007) 295-304
15. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 37 (2001) S9-S15
16. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23 (2005) 1126-1136
17. 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J. Nucl. Med. 47 (2006) 1707-1716
18. Cai W., Olafsen T., Zhang X., Cao Q., Gambhir S.S., Williams L.E., et al. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J. Nucl. Med. 48 (2007) 304-310
19. Olafsen T., Kenanova V.E., Sundaresan G., Anderson A.L., Crow D., Yazaki P.J., et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res. 65 (2005) 5907-5916
20. Rothe A., Nathanielsz A., Hosse R.J., Oberhauser F., Strandmann E.P., Engert A., et al. Selection of human anti-CD28 scFvs from a T-NHL related scFv library using ribosome display. J. Biotechnol. 130 (2007) 448-454
21. Luginbuhl B., Kanyo Z., Jones R.M., Fletterick R.J., Prusiner S.B., Cohen F.E., et al. Directed evolution of an anti-prion protein scFv fragment to an affinity of 1 pM and its structural interpretation. J. Mol. Biol. 363 (2006) 75-97
22. Schier R., McCall A., Adams G.P., Marshall K.W., Merritt H., Yim M., et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 263 (1996) 551-567
23. Zhou Y., Drummond D.C., Zou H., Hayes M.E., Adams G.P., Kirpotin D.B., and Marks J.D. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J. Mol. Biol. 371 (2007) 934-947
24. Nygren P.Å., and Skerra A. Binding proteins from alternative scaffolds. J. Immunol. Methods 290 (2004) 3-28
25. Hey T., Fiedler E., Rudolph R., and Fiedler M. Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol. 23 (2005) 514-522
26. Binz H.K., Amstutz P., and Pluckthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat. Biotechnol. 23 (2005) 1257-1268
27. Lipovsek D., Lippow S.M., Hackel B.J., Gregson M.W., Cheng P., Kapila A., and Wittrup K.D. Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies. J. Mol. Biol. 368 (2007) 1024-1041
28. Zahnd C., Wyler E., Schwenk J.M., Steiner D., Lawrence M.C., McKern N.M., et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J. Mol. Biol. 369 (2007) 1015-1028
29. Nilsson F.Y., and Tolmachev V. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr. Opin. Drug Discovery Dev. 10 (2007) 167-175
30. Tolmachev V., Orlova A., Nilsson F.Y., Feldwisch J., Wennborg A., and Abrahmsen L. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin. Biol. Ther. 7 (2007) 555-568
31. Andersson M., Rönnmark J., Arestrom I., Nygren P.Å., and Ahlborg N. Inclusion of a non-immunoglobulin binding protein in two-site ELISA for quantification of human serum proteins without interference by heterophilic serum antibodies. J. Immunol. Methods 283 (2003) 225-234
32. Grönwall C., Sjöberg A., Ramström M., Höiden-Guthenberg I., Hober S., Jonasson P., and Ståhl S. Affibody-mediated transferrin depletion for proteomics applications. Biotechnol. J. 2 (2007) 1389-1398
33. Renberg B., Shiroyama I., Engfeldt T., Nygren P.K., and Karlstrom A.E. Affibody protein capture microarrays: synthesis and evaluation of random and directed immobilization of affibody molecules. Anal. Biochem. 341 (2005) 334-343
34. Nord K., Gunneriusson E., Ringdahl J., Ståhl S., Uhlén M., and Nygren P.Å. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat. Biotechnol. 15 (1997) 772-777
35. Pavoni E., Flego M., Dupuis M.L., Barca S., Petronzelli F., Anastasi A.M., et al. Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein. BMC Cancer 6 (2006) 41
36. Orlova A., Magnusson M., Eriksson T.L., Nilsson M., Larsson B., Höiden-Guthenberg I., et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 66 (2006) 4339-4348
37. HER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J. Nucl. Med. 47 (2006) 846-853
38. Orlova A., Tolmachev V., Pehrson R., Lindborg M., Tran T., Sandstrom M., et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 67 (2007) 2178-2186
39. 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur. J. Nucl. Med. Mol. Imaging 34 (2007) 722-733
40. Baum R.P., Orlova A., Tolmachev V., and Feldwich J. A novel molecular imaging agent for diagnosis of recurrent HER2 positive breast cancer. First time in human study using an Indium-111- or Gallium-68-labelled Affibody molecule. Abstracts of Annual Congress of the European Association of Nuclear Medicine, Athens, Greece (2006). Eur. J. Nucl. Med. Mol. Imaging 33 (2006) S91
41. Friedman M., Nordberg E., Hoiden-Guthenberg I., Brismar H., Adams G.P., Nilsson F.Y., et al. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng. Des. Sel. 20 (2007) 189-199
42. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur. J. Nucl. Med. Mol. Imaging 34 (2007) 1843-1853
43. 99mTc to tumor-targeting Affibody molecules. Bioconjugate Chem. 18 (2007) 549-558
44. Behr T.M., Gotthardt M., Barth A., and Behe M. Imaging tumors with peptide-based radioligands. Q. J. Nucl. Med. 45 (2001) 189-200
45. Kennel S.J., Mirzadeh S., Hurst G.B., Foote L.J., Lankford T.K., Glowienka K.A., et al. Labeling and distribution of linear peptides identified using in vivo phage display selection for tumors. Nucl. Med. Biol. 27 (2000) 815-825
46. 111In]Bz-DTPA-hEGF in normal mice. Cancer Biother. Radiopharm. 19 (2004) 491-501
47. Divgi C.R., Welt S., Kris M., Real F.X., Yeh S.D., Gralla R., et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J. Natl. Cancer Inst. 83 (1991) 97-104
48. 131I-labeled epidermal growth factor. Clin. Cancer Res. 2 (1996) 13-20
49. Scott A.M., Lee F.T., Tebbutt N., Herbertson R., Gill S.S., Liu Z., et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc. Natl Acad. Sci. USA 104 (2007) 4071-4076
50. 111In]Bz-DTPA-hEGF: preparation and in vitro characterization of a potential anti-glioblastoma targeting agent. Cancer Biother. Radiopharm. 18 (2003) 643-654
51. Velikyan I., Sundberg A.L., Lindhe O., Hoglund A.U., Eriksson O., Werner E., et al. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J. Nucl. Med. 46 (2005) 1881-1888
52. Behr T.M., Goldenberg D.M., and Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur. J. Nucl. Med. 25 (1998) 201-212
53. Rüther U. pUR 250 allows rapid chemical sequencing of both DNA strands of its inserts. Nucleic Acids Res. 10 (1982) 5765-5772
54. Grönwall C., Jonsson A., Lindstrom S., Gunneriusson E., Stahl S., and Herne N. Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides. J. Biotechnol. 128 (2007) 162-183
55. Studier F.W., Rosenberg A.H., Dunn J.J., and Dubendorff J.W. Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol. 185 (1990) 60-89
56. Hansson M., Ringdahl J., Robert A., Power U., Goetsch L., Nguyen T.N., et al. An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein. Immunotechnology 4 (1999) 237-252
57. Horak E., Heitner T., Robinson M.K., Simmons H.H., Garrison J., Russeva M., et al. Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Cancer Biother. Radiopharm. 20 (2005) 603-613
58. Orlova A., Bruskin A., Sjostrom A., Lundqvist H., Gedda L., and Tolmachev V. Cellular processing of (125)I- and (111)In-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells. Nucl. Med. Biol. 27 (2000) 827-835